Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00340834 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,292
- Enrollment target
NCT00340834 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,292 participants.
The verdict
NCT00340834, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,292 participants
- Enrollment target
Study Summary
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
Interventions
- DRUG Fingolimod 1.25 mg
- DRUG Fingolimod 0.5 mg
- DRUG Interferon β-1a 30 µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,292 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00340834
The ClinicalTrials.gov registry entry for NCT00340834 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fingolimod 1.25 mg is the first listed.
NCT00340834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00340834 about?
NCT00340834 is a clinical study titled "Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase". This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
What is the current status of trial NCT00340834?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,292 participants. The study started on 2006-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00340834?
The interventions under investigation include: Fingolimod 1.25 mg (DRUG), Fingolimod 0.5 mg (DRUG), Interferon β-1a 30 µg (DRUG).
Who is sponsoring clinical trial NCT00340834?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.